GLP-1 agonisti u liječenju pretilosti

master's thesis

• Title (english): GLP-1 agonists in the treatment of obesity
• Author: Katarina Topić
• Mentor: Petra Turčić (mentor)
• Committee member: Petra Turčić (predsjednik povjerenstva)
• Committee member: Lidija Bach-Rojecky (član povjerenstva)
• Committee member: Ivana Perković (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology); Zagreb
• Defense date and country: 2023-06-29, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Agonisti GLP-1 receptora su lijekovi koji pripadaju skupini mimetika inkretina. Njihov glavni mehanizam
djelovanja uključuje stimulaciju sekrecije inzulina kao odgovor na oralni unos glukoze djelujući na β-stanice
gušterače te smanjenje lučenja glukagona istovremeno djelujući na α-stanice gušterače. GLP-1 R su široko
rasprostranjeni u organizmu pa tako GLP-1 RA imaju i brojne druge učinke u organizmu, kao npr. smanjenje
tjelesne mase jer djeluju na centar za sitost u mozgu. Primarna indikacija GLP-1 RA je liječenje nedovoljno
kontrolirane šećerne bolesti tipa 2, a nova indikacija im je dodatak dijeti sa smanjenim unosom kalorija i
povećanoj fizičkoj aktivnosti za kontrolu tjelesne težine kod osoba koje imaju ITM ≥ 30 kg/m2
ili ITM ≥ 27kg/m2 s komorbiditetom. Za tu indikaciju registrirani su liraglutid i semaglutid. Kliničke studije pokazuju
odlične rezultate u smanjenju tjelesne mase uslijed korištenja liraglutida i semaglutida. Nuspojave koje se
javljaju pri primjeni svih GLP-1 RA su mučnina, povraćanje, dijareja i konstipacija. Zabilježeno je i nekoliko
slučajeva nuspojava povezanih sa žučnim mjehurom.

Abstract (english)

GLP-1 receptor agonists are medications that belong to the group of incretin mimetics. Their main
mechanism of action involves stimulating insulin secretion in response to oral glucose intake by acting on
pancreatic β-cells and reducing glucagon secretion by acting on pancreatic α-cells. GLP-1 receptors are
widely distributed in the body, so GLP-1 receptor agonists also have numerous other effects in the body, such
as reducing body weight by acting on the satiety center in the brain. The primary indication for GLP-1
receptor agonists is the treatment of inadequately controlled type 2 diabetes, and their new indication is as
an adjunct to a reduced-calorie diet and increased physical activity for weight control in individuals with a
body mass index (BMI) ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with comorbidity. Liraglutide and semaglutide are
registered for this indication. Clinical studies show excellent results in reducing body weight with the use of
liraglutide and semaglutide. Common side effects associated with the use of all GLP-1 receptor agonists
include nausea, vomiting, diarrhea, and constipation. Several cases of side effects related to the gallbladder
have also been reported.

• Keywords: pretilost; GLP-1 agonisti; semaglutid; liraglutid
• Keywords (english): obesity; GLP-1 agonists; semaglutide; liragliutide
• Language: croatian
• URN:NBN: urn:nbn:hr:163:775333
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2023-11-21 14:22:35